Prosecution Insights
Prosecution Insights
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (60%) |
| §112 only | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LI, BAO Q | 1 | 75.5% | +26.4% |
| RZECZYCKI, PHILLIP MATTHEW | 1 | 63.0% | +39.1% |
| HOLLAND, PAUL J | 1 | 57.3% | +64.7% |
| KUCHARCZK, JED A | 1 | 79.6% | +16.9% |
| RIGA, MICHAEL ANGELO | 1 | 56.7% | +59.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17617895 | PURMORPHAMINE AS A SMALL COMPOUND POSITIVE ALLOSTERIC MODULATOR OF SECRETIN RECEPTOR FOR THE TREATMENT OF HYPERTENSION | KUCHARCZK, JED A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17434513 | RECOMBINANT VECTORS COMPRISING ARYLSULFATASE A AND THEIR USES IN STEM CELL THERAPY FOR THE TREATMENT OF METACHROMATIC LEUKODYSTROPHY | RIGA, MICHAEL ANGELO | 87d overdue |
| 17930591 | COMPOSITIONS IMMUNOGENIC AGAINST SARS CORONAVIRUS 2, METHODS OF MAKING, AND USING THEREOF | HOLLAND, PAUL J | 23d |
| 18267931 | COMPOSITIONS IMMUNOGENIC AGAINST INFLUENZA AND SARS CORONAVIRUS 2, METHODS OF MAKING AND USING THEREOF | LI, BAO Q | — |
| 18316254 | COMPOUNDS AFFECTING PIGMENT PRODUCTION AND METHODS FOR TREATMENT OF BACTERIAL DISEASES | RZECZYCKI, PHILLIP MATTHEW | — |
| 17617895 | PURMORPHAMINE AS A SMALL COMPOUND POSITIVE ALLOSTERIC MODULATOR OF SECRETIN RECEPTOR FOR THE TREATMENT OF HYPERTENSION | KUCHARCZK, JED A | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| 1625 | 1 |
| 1656 | 1 |
| 1623 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18267931 | COMPOSITIONS IMMUNOGENIC AGAINST INFLUENZA AND SARS CORONAVIRUS 2, METHODS OF MAKING AND USING THEREOF | LI, BAO Q | 1671 | §103 | Non-Final OA | — | Pending | Jun 16, 2023 |
| 18316254 | COMPOUNDS AFFECTING PIGMENT PRODUCTION AND METHODS FOR TREATMENT OF BACTERIAL DISEASES | RZECZYCKI, PHILLIP MATTHEW | 1625 | §112 | Final Rejection | — | Pending | May 12, 2023 |
| 17930591 | COMPOSITIONS IMMUNOGENIC AGAINST SARS CORONAVIRUS 2, METHODS OF MAKING, AND USING THEREOF | HOLLAND, PAUL J | 1656 | §103 | Final Rejection | 23d | Pending | Sep 08, 2022 |
| 17617895 | PURMORPHAMINE AS A SMALL COMPOUND POSITIVE ALLOSTERIC MODULATOR OF SECRETIN RECEPTOR FOR THE TREATMENT OF HYPERTENSION | KUCHARCZK, JED A | 1623 | §102§103§112 | Final Rejection | — | Pending | Dec 09, 2021 |
| 17434513 | RECOMBINANT VECTORS COMPRISING ARYLSULFATASE A AND THEIR USES IN STEM CELL THERAPY FOR THE TREATMENT OF METACHROMATIC LEUKODYSTROPHY | RIGA, MICHAEL ANGELO | 1634 | §103 | Final Rejection | 87d overdue | Pending | Aug 27, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial